Résumés
Résumé
Les RAMP (receptor activity-modifying protein) modifient le caractère fonctionnel des récepteurs couplés aux protéines G (RCPG) des peptides de la famille de la calcitonine. Il semble que l’on puisse étendre l’interaction des RAMP à d’autres RCPG de classe II, puisque ces protéines s’associent aux récepteurs de l’hormone parathyroïdienne, du glucagon et du VIP/PACAP (vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide) dénommé également R-VPAC1 (vasoactive-intestinal peptide PACAP receptor 1). Une fonction nouvelle des RAMP émerge de ces observations, car le complexe RAMP2/R-VPAC1 potentialise la voie de signalisation des phospho-inositides. La régulation de l’expression des RAMP à un niveau transcriptionnel ou post-transcriptionnel revêt une certaine importance, puisqu’elle peut influencer la réponse d’une cellule cible à un ligand, en modifiant le caractère fonctionnel d’un RCPG de classe II ou en affectant le niveau d’une voie de signalisation de ces récepteurs.
Summary
RAMPs (receptor activity-modifying proteins) were discovered in 1998 as accessory proteins needed to the functionnal activity of CGRP (calcitonin gene-related peptide) receptors. Three RAMPs generated by three different genes are known in human, rat and mice. The coding sequences of such genes are described, but as yet, regulation sequences are unknown. RAMPs interact with GPCR (G protein-coupled receptors) of class II. In the case of the calcitonin/CGRP peptide family, RAMPs determine the functionnal specificity of the receptor, glycosylate and translocate the receptor to the cell surface. CGRP receptors are observed in presence of the RAMP1/calcitonin receptor-like receptor (CRLR), but the association of RAMP2 or RAMP3 with CRLR generates an adrenomedullin receptor. The calcitonin receptor (CTR) is translocated alone to the cell surface, but interactions of RAMPs with CTR forms amylin receptors. If RAMPs can interact with glucagon, parathyroid hormone and VIP/PACAP (vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide (VPACR1)) receptors, the functionnal specificity of these receptors remains unaltered. However, the complex VPACR1/RAMP2 enhances specifically the phosphoinoside signaling pathway.
Parties annexes
Références
- 1. Brady AE, Limbird LE. G protein-coupled receptor interacting proteins : Emerging roles in localization and signal transduction. Cell Signal 2002 ; 14 : 297-309.
- 2. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors : Molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocrinol Rev 1996 ; 17 : 533-85.
- 3. Dennis T, Fournier A, Cadieux A, et al. hCGRP8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery. J Pharmacol Exp Ther 1990 ; 254 : 123-8.
- 4. Quirion R, Van Rossum D, Dumont Y, et al. Characterization of CGRP1 and CGRP2 receptor subtypes. Ann NY Acad Sci 1992 ; 657 : 88-105.
- 5. Chakravarty P, Suthar TP, Coppock HA, et al. CGRP and adrenomedullin binding correlates with transcript levels for calcitonin receptor-like receptor (CRLR) and receptor activity-modifyng proteins (RAMPs) in rat tissues. Br J Pharmacol 2000 ; 130 : 189-95.
- 6. Wimalawansa SJ. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin : A peptide superfamily. Crit Rev Neurobiol 1997 ; 11 : 167-239.
- 7. Nandha KA, Taylor GM, Smith DM, et al. Specific adrenomedullin binding sites and hypotension in the rat systemic vascular bed. Regul Pept 1996 ; 62 : 145-51.
- 8. McLatchie L, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin receptor like receptor. Nature 1998 ; 393 : 333-9.
- 9. Evans BN, Rosenblatt MI, Mnayer LO, et al. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem 2000 ; 275 : 31438-43.
- 10. Luebke AE, Dahl GP, Roos BA, Dickerson IM. Identification of a protein that confers CGRP responsiveness to oocytes using CFTR assay. Proc Natl Acad Sci USA 1996 ; 93 : 3455-60.
- 11. Prado MA, Evans-Bain B, Oliver KR, Dickerson IM. The role of the CGRP-receptor component protein (RCP) in adrenomedullin receptor signal transduction. Peptides 2001 ; 22 : 1773-81.
- 12. Prado MA, Evans-Bain B, Dickerson IM. Receptor component protein (RCP) : A member of a multi-protein complex required for G-protein-coupled signal transduction. Biochem Soc Trans 2002 ; 30 : 460-4.
- 13. Naghashpour M, Dahl G. Sensitivity of myometrium to CGRP varies during mouse estrous cycle and in response to progesterone. Am J Physiol Cell Physiol 2000 ; 278 : C561-9.
- 14. Njuki F, Nicholl CG, Howard A, et al. A new calcitonin-receptor-like sequence in rat pulmonary blood vessels. Clin Sci 1993 ; 85 : 385-8.
- 15. Edvinsson L, Sams A, Jansen-Olesen I, et al. Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries. Eur J Pharmacol 2001 ; 415 : 39-44.
- 16. Chauhan M, Thota CS, Kondapaka S, et al. Evidence for the existence of a new receptor for CGRP, which is not CRLR. Peptides 2003 ; 24 : 65-71.
- 17. Sexton PM, Albiston A, Morfis M, Tilakaratne N. Receptor activity modifying proteins. Cell Signal 2001 ; 13 : 73-83.
- 18. Buhlmann N, Aldeoca A, Leuthauser K, et al. Glycosylation of the calcitonin receptor like receptor at Asn(60) or Asn(112) is important for cell surface expression. FEBS Lett 2000 ; 486 : 320-4.
- 19. Flahaut M, Rossier BC, Firsov D. Respective roles of calcitonin receptor-like receptor (CRLR) and receptor activity-modifying proteins (RAMP) in cell surface expression of CRLR/RAMP heterodimeric receptors. J Biol Chem 2002 ; 277 : 14731-7.
- 20. Christopoulos G, Perry KJ, Morfis M, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 1999 ; 56 : 235-42.
- 21. Christopoulos A, Christopoulos G, Morfis M, et al. Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem 2003 ; 278 : 3293-7.
- 22. Poyner DR, Sexton PM, Marshall I, et al. International union of pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002 ; 54 : 233-46.
- 23. Armour SL, Foord S, Kenakin T, Chen WJ. Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor. J Pharmacol Toxicol Meth 1999 ; 42 : 217-24.
- 24. Muff R, Buhlmann N, Fisher JA, Born W. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying protein. Endocrinology 1999 ; 140 : 2924-27.
- 25. Kuwasako K, Kitamura K, Nagoshi Y, Eto T. Identification of the human receptor activity-modifying protein 1 domains responsible for agonist binding specificity. J Biol Chem 2003 ; 278 : 22623-30.
- 26. Foord SM, Marshall FH. RAMPs : Accessory proteins for seven transmembrane domain receptors. Trends Pharmacol Sci 1999 ; 20 : 184-7.
- 27. Aldecoa A, Gujer R, Fisher JA, Born W. Mammalian calcitonin receptor-like receptor/receptor activity modifying protein complexes define calcitonin gene-related peptide and adrenomedullin receptors in Drosophila Schneider 2 cells. FEBS lett 2000 ; 471 : 156-60.
- 28. Hilairet S, Foord SM, Marshall FH, Bouvier M. Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the receptor activity-modifying proteins. J Biol Chem 2001 ; 276 : 29575-81.
- 29. Gujer R, Aldecoa A, Buhlmann N, et al. Mutations of the asparagine 117 residue of a receptor activity-modifying protein 1 dependent human calcitonin gene-related peptide receptor result in selective loss of function. Biochemistry 2001 ; 40 : 5392-8.
- 30. Kuwasako K, Kitamura K, Ito K, et al. The seven amino acids of human RAMP2 (86) and RAMP3 (59) are critical for agonist binding to human adrenomedullin receptors. J Biol Chem 2001 ; 276 : 49459-65.
- 31. Tilakaratne N, Christopoulos G, Zumpe ET, et al. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther 2000 ; 294 : 61-72.
- 32. Totsune KO, Takahashi K, Mackenzie HS, et al. Increased gene expression of adrenomedullin and adrenomedullin-receptor complexes, receptor-activity modifying protein (RAMP)2 and calcitonin-receptor-like receptor (CRLR) in the heart of rats with congestive heart failure. Clin Sci 2000 ; 99 : 541-6.
- 33. Oie E, Vinge LE, Yndestad A, et al. Induction of a myocardial adrenomedullin signalling system during ischemic heart failure in rats. Circulation 2000 ; 101 : 415-22.
- 34. Cueille C, Pidoux E, De Vernejoul MC, Garel JM. Increased myocardial expression of RAMP1 and RAMP3 in rats with chronic heart failure. Biochem Biophys Res Commun 2002 ; 294 : 340-6.
- 35. Nagae T, Mukoyama M, Sugawara A, et al. Rat receptor-activity-modifying proteins (RAMPs) for adrenomedullin/CGRP receptor : Cloning and upregulation in obstructive nephropathy. Biochem Biophys Res Commun 2000 ; 270 : 89-93.
- 36. Ono Y, Okano I, Kojima M, et al. Decreased gene expression of adrenomedullin receptor in mouse lungs during sepsis. Biochem Biophys Res Commun 2000 ; 271 : 197-202.
- 37. Qing X, Svaren J, Keith IM. mRNA expression of novel CGRP1 receptors and their activity-modifying proteins in hypoxic rat lung. Am J Physiol Lung Cell Mol Physiol 2001 ; 280 : L547-54.
- 38. Frayon S, Cueille C, Gnidéhou S, et al. Dexamethasone increases RAMP1 and CRLR mRNA expressions in human vascular smooth muscle cells. Biochem Biophys Res Commun 2000 ; 270 : 1063-7.
- 39. Makino Y, Shibata K, Makino I, et al. Alteration of the adrenomedullin receptor component gene expression associated with the blood pressure in pregnancy-induced hypertension. J Clin Endocrinol Metab 2001 ; 86 : 5079-82.
- 40. Nowak W, Parameswaran N, Hall CS, et al. Novel regulation of adrenomedullin receptor by PDGF : Role of receptor activity modifying. Am J Physiol Cell Physiol 2002 ; 282 : C1322-31.
- 41. Roh J, Chang CL, Bhalla A, et al. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem 2004 ; 279 : 7264-74.